These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2885867)

  • 1. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
    Butler B; Bech P
    Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study.
    Möller HJ; Kissling W; Dietzfelbinger T; Stoll KD; Wendt G
    Pharmacopsychiatry; 1989 Jan; 22(1):38-41. PubMed ID: 2565583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia.
    Volz HP; Möller HJ; Gerebtzoff A; Bischoff S
    Eur Arch Psychiatry Clin Neurosci; 2002 Apr; 252(2):76-80. PubMed ID: 12111340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients.
    Wetzel H; Wiedemann K; Holsboer F; Benkert O
    Psychopharmacology (Berl); 1991; 103(2):280-3. PubMed ID: 1674161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenia: D4 receptor elevation. What does it mean?
    Seeman MV
    J Psychiatry Neurosci; 1994 May; 19(3):171-6. PubMed ID: 7913338
    [No Abstract]   [Full Text] [Related]  

  • 6. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
    Chouinard G
    J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients].
    Klieser E; Lehmann E; Tegeler J
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():14-7. PubMed ID: 1683333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.
    Klimke A; Klieser E
    Pharmacopsychiatry; 1991 Jul; 24(4):107-12. PubMed ID: 1684439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine.
    Herrmann WM; Schärer E; Delini-Stula A
    Pharmacopsychiatry; 1991 Nov; 24(6):196-205. PubMed ID: 1687485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
    Wiesel FA
    Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S; Soubrouillard C; Blin O
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose zotepine in the maintenance treatment of schizophrenia.
    Fleischhacker WW; Stuppäck C; Barnas C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):61-3. PubMed ID: 2883685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine receptors and the dopamine hypothesis of schizophrenia.
    Seeman P
    Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
    Keegan D
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S46-52. PubMed ID: 7533051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G; Chong SA
    J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.